Biogen (BIIB 343.20, +44.39) has spiked 14.9% in premarket after
the company's Phase II study of an anti-amyloid beta protofibril antibody
showed positive results in patients with early Alzheimer's disease. Today's
pre-market gain has lifted Biogen to levels not seen since early February.
Biogen's Study 201 is being conducted in collaboration with Japan's Eisai. Shares of Eisai spiked 19.5% in Tokyo overnight.
Last evening, the two companies announced that Study 201, a study of 856 patients with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia, achieved statistical significance on key endpoints at 18 months. The study showed slowing progression in Alzheimer's Disease Composite Score and a reduction of amyloid accumulated in the brain, measured with a PET scan.
The drug candidate showed acceptable tolerability profile through 18 months of administration with infusion-related reactions representing the most common side effect. These reactions were mostly mild to moderate in severity. The two companies will present detailed results of the study at future academic conferences.
Eisai's Chief Clinical Officer and Chief Medical Officer of the company's Neurology Business Group, Lynn Kramer, M.D., commented on the results, saying "This is the first late-stage anti-amyloid antibody study to successfully achieve statistically significant results at 18 months, further validating the amyloid hypothesis."
- OUR VIEW
- LEARNING CENTER